Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition.
Young HL, Rowling EJ, Bugatti M, Giurisato E, Luheshi N, Arozarena I, Acosta JC, Kamarashev J, Frederick DT, Cooper ZA, Reuben A, Gil J, Flaherty KT, Wargo JA, Vermi W, Smith MP, Wellbrock C, Hurlstone A. Young HL, et al. Among authors: arozarena i. J Exp Med. 2017 Jun 5;214(6):1691-1710. doi: 10.1084/jem.20160855. Epub 2017 Apr 27. J Exp Med. 2017. PMID: 28450382 Free PMC article.
In melanoma, beta-catenin is a suppressor of invasion.
Arozarena I, Bischof H, Gilby D, Belloni B, Dummer R, Wellbrock C. Arozarena I, et al. Oncogene. 2011 Nov 10;30(45):4531-43. doi: 10.1038/onc.2011.162. Epub 2011 May 16. Oncogene. 2011. PMID: 21577209 Free PMC article.
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
Smith MP, Ferguson J, Arozarena I, Hayward R, Marais R, Chapman A, Hurlstone A, Wellbrock C. Smith MP, et al. Among authors: arozarena i. J Natl Cancer Inst. 2013 Jan 2;105(1):33-46. doi: 10.1093/jnci/djs471. Epub 2012 Dec 17. J Natl Cancer Inst. 2013. PMID: 23250956 Free PMC article.
MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide.
Erice O, Smith MP, White R, Goicoechea I, Barriuso J, Jones C, Margison GP, Acosta JC, Wellbrock C, Arozarena I. Erice O, et al. Among authors: arozarena i. Mol Cancer Ther. 2015 May;14(5):1236-46. doi: 10.1158/1535-7163.MCT-14-0810. Epub 2015 Mar 16. Mol Cancer Ther. 2015. PMID: 25777962
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.
Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, Dummer R, Frederick DT, Flaherty KT, Cooper ZA, Wargo JA, Wellbrock C. Smith MP, et al. Among authors: arozarena i. Cancer Cell. 2016 Mar 14;29(3):270-284. doi: 10.1016/j.ccell.2016.02.003. Cancer Cell. 2016. PMID: 26977879 Free PMC article.
51 results